Piper Jaffray analyst Edward Tenthoff upgraded Regeneron Pharmaceuticals to Overweight saying that while Eylea growth is slowing, new approvals are coming. The analyst expects Dupixent approval in atopic dermatitis by the March 29 FDA action date and Phase III Liberty Asthma Quest data and potential supplemental Biologics License Application by year-end. In addition, the FDA has reviewed Sanofi's (SNY) Le Trait facility enabling a Kevzara refilling soon and potential approval in Q2, Tenthoff points out. He keeps a $446 price target for Regeneron shares. The stock closed Friday down 13c to $359.87.